MARCH, 2009

A PREVIEW OF VALOIS PHARMA'S SIDE-ACTUATED NASAL SPRAY DEVICE

Valois Pharma will unveil a new and innovative side-actuated device for nasal drug delivery at the upcoming Nasal Drug Delivery conference, organized by Management Forum and to be held in London on April 1st and 2nd. This easy to use device, designed for improved patient comfort, is highly customizable.

An optimized device, the fruit of many years of research and two years of development

Always listening to what the market is saying and what patients are asking for, Valois Pharma conducted a series of patient acceptance studies in the UK and the US to understand nasal spray user preferences and expectations. Valois Pharma's R&D teams worked for a number of years to deliver a patented and market-ready side-actuated device that would make nasal drug delivery easier and meet the concerns of some patients who were dissatisfied with classic top-actuated nasal sprays.

Ease of use and comfort : real benefits for patients

The first benefit that Valois Pharma's side-actuated device delivers is that it is easy to use. Not only for self-administration, but also for third-party administration, especially in pediatric use. Compact, ergonomically designed and intuitive to use, the device requires only moderate effort to actuate it. This means that it can be used by a wide range of people, from adolescents to the elderly.

Next, but by no means least, is patient comfort. Using the side-actuator removes any possibility of axial movement of the nozzle inside the nostril when the actuator is pressed. This eliminates any risk of the nozzle entering the nostril too deeply. Moreover there is no contact between fingers and nostrils which improves hygiene during treatment. In addition, the device is fitted with a level indicator which allows the patient to easily see the amount of drug left and to replace medication early before it runs out. Finally, as the movement to actuate the device is perfectly natural, it is much easier to obtain delivery of a full dose.

A customizable device for the pharmaceutical industry

Valois Pharma's side-actuated nasal spray device consists of a standard actuator coupled with a customizable shell and cap. This modular design is a real market advantage for pharmaceutical companies who want to reinforce their branding with an in-house style. The current focus is on nasal delivery of Rx drugs, and in particular treatment of allergic rhinitis. However future development and improvements such as integration of a dose counter could see the device being used for systemic nasal drug delivery as well.

Aiming for optimal patient compliance

Valois Pharma offers integration of its side-actuated nasal spray device, which combines ease of use with patient comfort, with Equadel®, the first pump that dispenses the same dose and spray every time, regardless of how much pressure is exerted by the patient. This solution reinforces patient compliance which in turn will lead to improved drug effectiveness.

Valois Pharma, a division of Valois S.A.S, specializes in nasal and pulmonary drug delivery technologies with a broad product range that also provides solutions for other drug delivery routes such as buccal/sub-lingual, throat and dermal/transdermal.

Valois S.A.S., founded in 1947, is a world leader in the design, development and manufacture of proprietary spray, aerosol and alternative dispensing systems for the Pharmaceutical, Perfumery and Cosmetics markets. Valois S.A.S. is a wholly owned subsidiary of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Press contact:

Marie-Cécile Lachaux-Disle, press manager
Tel.: +33 (0)1 39 17 20 41 - **Fax:** +33 (0)1 39 58 12 98 - **Email:** marie-cecile.lachaux-disle@valois.com

PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE